TRVN - Trevena, Inc.
After hours:
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.0600 |
| Open | 1.0700 |
| Bid | 1.0100 x 1000 |
| Ask | 1.0700 x 800 |
| Day's Range | 0.9501 - 1.0900 |
| 52 Week Range | 0.5800 - 12.2250 |
| Volume | |
| Avg. Volume | 2,845,709 |
| Market Cap | 11.848M |
| Beta (5Y Monthly) | 2.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.4200 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
Fair Value
Related Research
GlobeNewswireTrevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first commercial sale in China CHESTERBROOK, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received a $3 millio
- GlobeNewswire
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones
CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Compan
- GlobeNewswire
Trevena Reports First Quarter 2023 Results and Provides Business Update
OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million non-dilutive tranche from R-Bridge upon first commercial sale of OLINVYK in China TRV045 topline data expected in 3Q 2023 for two proof-of-concept studies supporting continued development for potential use in epilepsy and chronic pain Previously announced initial topline OLINVYK data demonstrated a statis
ZacksAspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
Aspira (AWH) delivered earnings and revenue surprises of -1,360% and 0.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
Company to host a Conference Call & Webcast at 8:00 a.m. ETCHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023. The Company will host a conference call and webcast
- GlobeNewswire
Trevena Announces Approval of OLINVYK in China
Trevena’s partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15 million to Trevena expected on first commercial sale in China, based on ex-US Royalty-Based Financing with R-Bridge Healthcare Fund, an affiliate of CBC Group CHESTERBROOK, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and comme
- GlobeNewswire
Trevena to Participate in Three Upcoming Conferences
CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that members of Management will participate in three upcoming conferences. JMP Securities Life Sciences ConferenceDate: May 15th to May 16th, 2023Location: New York, NY BIO International ConventionDate: June 5th to June 8th, 2023Location: Boston, M
Insider MonkeyTrevena, Inc. (NASDAQ:TRVN) Q4 2022 Earnings Call Transcript
Trevena, Inc. (NASDAQ:TRVN) Q4 2022 Earnings Call Transcript March 31, 2023 Operator: Greetings, and welcome to the Trevena Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Barry Shin, Chief Financial Officer for Trevena. Thank you. […]
- GlobeNewswire
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study
OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR analysis of ARTEMIS patients at Wake Forest Baptist Health OLINVYK-treated patients had a 52.2% GI complete responder rate, defined as no vomiting and no antiemetic use throughout the post-operative period, based on initial topline data from the VOLITION (n=203) real world outcomes study Over
- GlobeNewswire
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor modulator, continues to advance as a potential treatment for epilepsy, diabetic neuropathic pain and other CNS disorders, with two proof-of-concept studies expected to complete enrollment by mid-2023 Cash balance of $38.3 million at year end 2022 Company to host conference call today, March 30, 2023 at 8:00 a
- GlobeNewswire
Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
Company to host a Conference Call & Webcast at 8:00 a.m. ETCHESTERBROOK, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, prior to the market open on Thursday, March 30, 2023. The Company will host a conf
ZacksTrevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.
- GlobeNewswire
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders
New study complements the ongoing proof-of-concept study, and will provide further insight into TRV045 target engagement and mechanism of action for the potential treatment of epilepsy and other CNS disordersCHESTERBROOK, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a Phase 1 proof-of-c
- GlobeNewswire
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY
OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects Study consistent with prior results that suggest OLINVYK provides a reduced impact on ventilatory function as compared to IV morphine CHESTERBROOK, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today
- GlobeNewswire
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement
New Phase 1 clinical study designed to build on nonclinical evidence of anti-inflammatory signaling and potential disease-modifying effect of TRV045 in the treatment of epilepsy and other CNS disorders TRV045, a novel S1P receptor modulator, is highly specific for S1PR subtype 1 and reported no lymphopenia in a prior Phase 1 clinical study CHESTERBROOK, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercializatio
- GlobeNewswire
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting OLINVYK poster presentation on reduced effect on neurocognitive function in humans compared to morphine presented at ACNP Annual Meeting OLINVYK comparison analysis versus other opioid treatments showed reduced gastrointestinal adverse effects presented at American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting C
- GlobeNewswire
Trevena Regains Compliance with Nasdaq Listing Requirements
CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq
- GlobeNewswire
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CHESTERBROOK, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,614,380 shares of common stock and warrants to purchase up to an aggregate of 2,614,380 share
- GlobeNewswire
Trevena Announces Reverse Stock Split
CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the “Amendment”) to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 5:01 p.m. ET on Wednesd
ZacksTrevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates
Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia Nonclinical study showed anti-inflammatory signaling, suggesting a potential disease-modifying effect of TRV045 in the treatment of epilepsy, based on astrocyte cell culture study PK profile supports anticipated once daily dosing CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicin
- GlobeNewswire
Trevena Reports Third Quarter 2022 Results and Provides Business Update
OLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement Positive Phase 1 topline results for TRV045, a novel S1P receptor modulator; no serious adverse events and PK profile supports anticipated once daily dosing Targeted TRV045 proof-of-concept study to assess CNS activity planned for early 2023 Cash balance of $40.4 million at Q3 funds operations into Q3 2023 Company to host conference call today, November 9, 2022 at 8:00 a.m. ET CHES
- GlobeNewswire
Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022
Company to host a Conference Call & Webcast at 8:00 a.m. ETCHESTERBROOK, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2022, prior to the market open on Wednesday, November 9, 2022. The Company will host a conference call
- GlobeNewswire
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
OLINVYK study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects OLINVYK oral presentation was selected as “Best of Abstracts: Clinical Science” at the American Society of Anesthesiologists (ASA) 2022 annual meeting CHESTERBROOK, Pa., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with
